Mingyue Optical Lens Co (301101) Fair Value & Analysis

Healthcare · CN · Market cap 6.0B CNY

Analysis

Mingyue Optical Lens Co (301101) currently trades at ¥29.31, while our model-based Fair Value estimate is ¥21.06 — implying the stock looks roughly 28.1% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Mingyue Optical Lens Co.,Ltd. engages in the research and development, design, and production of lenses, lens raw materials, finished mirrors, frames, and other products in China and internationally. The company offers high refractive index, dual blue light protection, PMC super bright, KR super tough, polarized, intelligent color changing, and progressive multifocus lenses; and customized functional products, such as juvenile myopia management, KR super toughness, smart color change, progressive multifocal, anti-fatigue, high degree of high astigmatism, postoperative protection, outdoor polarized myopia sunglasses, and other product series. It also engages in wholesale and retail trade; and technology promotion and application service industry. Mingyue Optical Lens Co.,Ltd. was founded in 2002 and is based in Danyang, China.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.